Actinium Pharmaceuticals WKN: A2QA48 ISIN: US00507W2061 Forum: Aktien Thema: Hauptdiskussion

Zusammenfassung des Calls heute: 1) Dr. Giralt stresses that outcomes will improve even more with maintenence therapy which was not allowed for Iomab patients in the sierra trial vs. control arm 2) Iomab referred to "paridigm changing" and "optimal strategy", best strategy to bridge patients that have relapsed and that are old", paving the way to standard of care 3) Recent approved targeted therapies are no long term disease control 4) There is no sense in trying to replicate control arm outcomes by hoping someone fails chemo in order to give them iomab. his recommendation: straight to iomab 5) Further indications: MDS and any cd45 related malignancies 6) No competition on the horizon including jasper 7) Early access news coming middle of the year, thats about 3 months! 8) Early access will include all 22 current sierra sites and will increase to about 50 sites. these 50 are the ones they are targeting at the launch of commercialization 9) Approval expected 2024

Auf stockwits wurde heute geschrieben, dass der IBB ishare Biotech ETF mit 200k shares eingestiegen ist. Keine Ahnung, ob das stimmt. Wenn ja, wird es vielleicht Nachahmer geben 😉